Burkhardt C, Kelly J P, Lim Y H, Filley C M, Parker W D
Department of Neurology, University of Colorado School of Medicine, Denver.
Ann Neurol. 1993 May;33(5):512-7. doi: 10.1002/ana.410330516.
Neuroleptic medications are prescribed to millions of patients, but their use is limited by potentially irreversible extrapyramidal side effects. Haloperidol shows striking structural similarities to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which produces parkinsonism apparently through inhibition of NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial electron transport chain. We now report that haloperidol, chlorpromazine, and thiothixene inhibit complex I in vitro in rat brain mitochondria. Clozapine, an atypical antipsychotic reported to have little or no extrapyramidal toxicity, also inhibits complex I, but at a significantly higher concentration. Neuroleptic treated patients have significant depression of platelet complex I activity similar to that seen in idiopathic Parkinson's disease. Complex I inhibition may be associated with the extrapyramidal side effects of these drugs.
数以百万计的患者都在使用抗精神病药物,但其应用受到潜在不可逆锥体外系副作用的限制。氟哌啶醇与神经毒素1-甲基-4-苯基-1,2,3,6-四氢吡啶在结构上有显著相似性,后者显然通过抑制线粒体电子传递链的NADH:泛醌氧化还原酶(复合体I)而产生帕金森综合征。我们现在报告,氟哌啶醇、氯丙嗪和硫利达嗪在体外可抑制大鼠脑线粒体中的复合体I。氯氮平是一种据报道几乎没有或完全没有锥体外系毒性的非典型抗精神病药物,它也能抑制复合体I,但所需浓度显著更高。接受抗精神病药物治疗的患者血小板复合体I活性明显降低,这与特发性帕金森病患者的情况相似。复合体I的抑制可能与这些药物的锥体外系副作用有关。